Nykode Therapeutics AS (CHIX:NYKDo)
kr 18.69 0 (0%) Market Cap: 2.06 Bil Enterprise Value: 666.43 Mil PE Ratio: 0 PB Ratio: 1.28 GF Score: 57/100

Q3 2022 Nykode Therapeutics ASA Earnings Call Transcript

Nov 23, 2022 / 03:00PM GMT
Operator

Greetings, and welcome to the Nykode Therapeutics' third-quarter 2022 financial results call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the call over to Chief Executive Officer, Michael Engsig. Thank you. You may begin.

Michael Engsig
Nykode Therapeutics ASA - CEO

Thank you very much. And also from our side, a warm welcome to all participants joining here, both from Europe and the early birds from the US. I'll start out with a quick note on the forward-looking statements. We assume you're all familiar with that. So on that note, we'll move forward. With me today here at this third-quarter call, I'm very pleased to have Agnete Fredriksen, our Co-Founder and Chief Business Officer; as well as Harald Gurvin, our Chief Financial Officer. I'm Michael Engsig, CEO of Nykode.

A quick introduction to those of you who are new to Nykode: Nykode is a Norwegian-based immunotherapy company. We're entirely focused to building the leading immunotherapy company. And we're focused, too, on our dual strategy,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot